Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7009880
Reference Type
Journal Article
Title
A 2020 update on the use of genetic testing for patients with primary immunodeficiency
Author(s)
Chinn, IK; Orange, JS; ,
Year
2020
Is Peer Reviewed?
Yes
Journal
Expert Review of Clinical Immunology
ISSN:
1744-666X
Publisher
TAYLOR & FRANCIS LTD
Location
ABINGDON
Volume
16
Issue
9
Page Numbers
897-909
PMID
32822560
DOI
10.1080/1744666X.2020.1814145
Web of Science Id
WOS:000567003400001
Abstract
Introduction Genetic testing of patients with clinically diagnosed or suspected primary immunodeficiencies (PIDs) constitutes standard of care. Choice of testing modality and patient attributes can impact the likelihood of securing a diagnosis. Areas covered Published diagnostic rates for gene panel testing, exome sequencing (WES), and whole genome sequencing are compared among cohorts identified within PubMed. Performance of the testing platforms is reviewed in PIDs taken as a whole, followed by separate cohorts of patients with suspected PIDs, specific PIDs, and clinical phenotypes that can be associated with underlying PIDs. Expert opinion Massively parallel high-throughput sequencing clearly represents the most expedient method for diagnosis of PIDs. For patients from highly consanguineous backgrounds, WES and whole genome sequencing should be performed to obtain optimal diagnostic yield. For patients for whom familial consanguinity is unlikely, choice of platform depends upon the phenotype. In patients with suspected PIDs, assessment for copy number variants is important, whether as part of gene panel bioinformatic analyses or combined with WES. Diagnostic rates overall for massively parallel sequencing are high for clinically diagnosed and suspected PIDs. WES may have a slightly higher overall yield, but gene panel testing represents a cost-effective and efficient reasonable initial step.
Keywords
Copy number variant; diagnostic rate; exome sequencing; gene panel; next generation sequencing; primary immunodeficiency; whole genome sequencing
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity